Latest stories on DARE
Daré Bioscience Updates Bylaws to Ease Shareholder Quorum
TipRanks50 · neutralgeneral
Dare Bioscience, Inc. (DARE) files 8-K
SEC 8-K50 · neutralgeneral
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
StockTitan56 · neutralproduct/pr
Dare Bioscience, Inc. (DARE) files 8-K
SEC 8-K50 · neutralgeneral
Dare Bioscience announces new $908,000 NIH funding award to advance DARE-PTB2
The Fly63 · neutralgeneral
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
GlobeNewswire50 · neutralgeneral
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Seeking Alpha56 · neutralproduct/pr
Dare Bioscience files to sell 8.93M shares of common stock for holders
The Fly28 · bearishgeneral
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
StockTitan63 · neutralproduct/pr
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment
Business Insider63 · neutralproduct/pr
Daré Bioscience Earnings Call: Promise Amid Tight Cash
TipRanks48 · neutralearnings
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript
Yahoo Finance53 · neutralearnings
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript
The Motley Fool56 · neutralearnings
Dare Bioscience, Inc. (DARE) files 8-K
SEC 8-K50 · neutralgeneral
Dare Bioscience announces pricing of $6M registered direct offering
The Fly28 · bearishgeneral
Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Business Insider28 · bearishgeneral
Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire28 · bearishgeneral
Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter
Seeking Alpha56 · neutralproduct/pr
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Dare Bioscience GAAP EPS of -$0.20 beats by $0.10, revenue of $187.5M
Seeking Alpha63 · neutralearnings
Dare Bioscience, Inc. (DARE) files 8-K
SEC 8-K50 · neutralgeneral
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances
GlobeNewswire58 · neutralproduct/pr
Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript
Seeking Alpha56 · neutralproduct/pr